Regeneron PharmaceuticalsREGN
REGN
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
2% more call options, than puts
Call options by funds: $1.19B | Put options by funds: $1.17B
1% less repeat investments, than reductions
Existing positions increased: 474 | Existing positions reduced: 480
6% less funds holding
Funds holding: 1,366 [Q3] → 1,285 (-81) [Q4]
5.98% less ownership
Funds ownership: 92.08% [Q3] → 86.1% (-5.98%) [Q4]
23% less first-time investments, than exits
New positions opened: 162 | Existing positions closed: 211
36% less capital invested
Capital invested by funds: $104B [Q3] → $66.3B (-$37.4B) [Q4]
39% less funds holding in top 10
Funds holding in top 10: 23 [Q3] → 14 (-9) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$738
16%
upside
Avg. target
$884
39%
upside
High target
$1,070
68%
upside
8 analyst ratings
5 positive
63%
3 neutral
38%
0 negative
0%
Baird Brian Skorney 27% 1-year accuracy 6 / 22 met price target | 19%upside $759 | Neutral Maintained | 5 Feb 2025 |
Leerink Partners David Risinger 45% 1-year accuracy 5 / 11 met price target | 31%upside $834 | Outperform Upgraded | 5 Feb 2025 |
Citigroup Geoff Meacham 65% 1-year accuracy 22 / 34 met price target | 18%upside $750 | Neutral Maintained | 28 Jan 2025 |
Piper Sandler Christopher Raymond 33% 1-year accuracy 10 / 30 met price target | 59%upside $1,013 | Overweight Maintained | 27 Jan 2025 |
UBS Trung Huynh 43% 1-year accuracy 3 / 7 met price target | 16%upside $738 | Neutral Downgraded | 16 Jan 2025 |
Financial journalist opinion
Based on 157 articles about REGN published over the past 30 days
Negative
The Motley Fool
2 days ago
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded down a wide variety of stocks in both fields.
Neutral
GlobeNewsWire
2 days ago
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Neutral
GlobeNewsWire
2 days ago
Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) prior to November 2023 and continue to hold any of those NASDAQ: REGN shares, should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Negative
Seeking Alpha
1 week ago
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led to increased competition and pricing pressures, impacting the company's revenue and profit margins. Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation.
Neutral
MarketBeat
2 weeks ago
3 Stocks With Ironclad Balance Sheets for Long-Term Stability
Although sometimes overshadowed by the all-important income statement, the balance sheet can offer essential insights into a company's financial health. It revolves around the balance between a company's assets and liabilities.
Neutral
PRNewsWire
2 weeks ago
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Matteo Paz, 18, of Pasadena, California , won the top award of $250,000 in the 2025 Regeneron Science Talent Search, the U.S.'s oldest and most prestigious science and math competition for high school seniors.
Neutral
GlobeNewsWire
2 weeks ago
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition $250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition
Neutral
Seeking Alpha
2 weeks ago
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET Company Participants Ryan Crowe - SVP, IR & Strategic Analysis Chris Fenimore - CFO Conference Call Participants David Risinger - Leerink Partners David Risinger All right. So we're going to get started.
Neutral
Accesswire
2 weeks ago
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").
Neutral
Accesswire
2 weeks ago
Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 – REGN
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135096&wire=1 or contact Joseph E. Levi, Esq.
Charts implemented using Lightweight Charts™